Home

Results 1 - 10 of 296,692 for treatment companies. Search took 5.734 seconds.  
Sort by date/Sort by relevance
FOR IMMEDIATE RELEASE Accelerating Access Initiative (AAI) - Fact Sheet Estimated number of people living with HIV in developing countries receiving antiretroviral (ARV) treatment with medicines provided by the AAI as of March 2005 • Established in 2000, the Accelerating Access Initiative (AAI) involves seven research- based pharmaceutical companies; Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Roche, and Merck & Co., Inc, and five United Nations partners; UNAIDS, the World Health Organization, World Bank, UNICEF, and the United Nations Population Fund (UNFPA) • The AAI combines pharmaceutical industry research knowledge with that of its partners to establish practical, long-term solutions that help to improve access to HIV healthcare in resource-poor countries • The AAI companies remain committed to dialogue with all external organisations sharing similar goals to help people living with HIV/AIDS in the poorest countries. AAI members are actively engaged with many groups focused towards making meaningful and practical differences on the ground Data on patients receiving treatment with ARV medicines provided by the AAI companies – Quarter 1 , 2005 • In March 2005, a total of 427,000 people living with HIV/AIDS in developing countries were receiving treatment with ARV medicines provided by the AAI companies • The total number of patients receiving treatment from the AAI companies increased by 47% on the previous year, with 130,000 people initiated on treatment during 2004 • In Africa alone, 216,000 patients are being treated with medicines supplied by the AAI companies. With an increase in excess of 121% on the previous year, there has been a 23-fold increase in Africa since the establishment of the AAI in May 2000 • The estimated number of people on treatment is based on actual quarterly drug supply data from the seven companies.
Language:English
Score: 1212672.5 - https://www.who.int/3by5/factsheet_AAI.pdf
Data Source: un
Although Stavudine is no longer used in developed countries, a majority of people in developing countries continue to receive some combination of treatment containing it because of its low cost, thanks to competition among multiple generic drug companies in countries where this drug is unpatented. (...) At the centre of this war is a very basic concept: the differentiation between the collective good of public health and profit‒seeking by private firms. An example of treatment franchising is Tibotec, an international pharmaceutical company owned by Johnson & Johnson that licensed production of the antiretroviral medicine Rilpivirine to one South African and two Indian manufacturers. (...) In Africa, drug stock-outs or not enrolling new HIV-infected persons into treatment are evidence of such situations.4 Governments and international institutions should make use of public health safeguards in opposing patent laws and granting exclusive rights to pharmaceutical companies.
Language:English
Score: 1190036.3 - https://www.un.org/en/node/27131
Data Source: un
Although Stavudine is no longer used in developed countries, a majority of people in developing countries continue to receive some combination of treatment containing it because of its low cost, thanks to competition among multiple generic drug companies in countries where this drug is unpatented. (...) At the centre of this war is a very basic concept: the differentiation between the collective good of public health and profit‒seeking by private firms. An example of treatment franchising is Tibotec, an international pharmaceutical company owned by Johnson & Johnson that licensed production of the antiretroviral medicine Rilpivirine to one South African and two Indian manufacturers. (...) In Africa, drug stock-outs or not enrolling new HIV-infected persons into treatment are evidence of such situations.4 Governments and international institutions should make use of public health safeguards in opposing patent laws and granting exclusive rights to pharmaceutical companies.
Language:English
Score: 1190036.3 - https://www.un.org/en/chronicl...d-access-newer-antiretrovirals
Data Source: un
Both GlaxoWellcome and SmithKline Beecham had a history of addressing developing world diseases in terms both of the R&D they undertook, and the efforts made to improve access to existing medicines GlaxoSmithKline makes very significant investments in researching new products to prevent and treat developing world diseases. The company has extensive research programmes in to both the prevention and treatment of the three diseases that are the focus of international efforts – HIV/AIDS, malaria and TB. (...) GlaxoSmithKline also has a dedicated specialist team within the company working on treatments for tropical diseases, with programmes to develop anti-malarials, de-worming agents, and antidiarrhoeals. (...) You will know that we have recently announced that the prices available through the AAI – which represent discounts of some 90% on world prices - are also being offered by GlaxoSmithKline to not-for-profit organisations that are able to deliver anti-retrovirals to patients in developing countries, including selling directly to aid organisations and UN agencies for use in their own programmes. Additionally the company is working with employers in Africa who offer HIV/AIDS care and treatment directly to their staff through their own workplace clinics.
Language:English
Score: 1189764.2 - https://www.wto.org/english/tr...resentations_e/14a_faber_e.doc
Data Source: un
Both GlaxoWellcome and SmithKline Beecham had a history of addressing developing world diseases in terms both of the R&D they undertook, and the efforts made to improve access to existing medicines GlaxoSmithKline makes very significant investments in researching new products to prevent and treat developing world diseases. The company has extensive research programmes in to both the prevention and treatment of the three diseases that are the focus of international efforts – HIV/AIDS, malaria and TB. (...) GlaxoSmithKline also has a dedicated specialist team within the company working on treatments for tropical diseases, with programmes to develop anti- malarials, de-worming agents, and antidiarrhoeals. (...) You will know that we have recently announced that the prices available through the AAI – which represent discounts of some 90% on world prices - are also being offered by GlaxoSmithKline to not-for-profit organisations that are able to deliver anti-retrovirals to patients in developing countries, including selling directly to aid organisations and UN agencies for use in their own programmes. Additionally the company is working with employers in Africa who offer HIV/AIDS care and treatment directly to their staff through their own workplace clinics.
Language:English
Score: 1189764.2 - https://www.wto.org/english/tr...resentations_e/14a_faber_e.pdf
Data Source: un
Since a cure exists, pharmaceutical companies are not interested in developing another treatment. (...) Additionally, because tuberculosis is a disease affecting mostly developing countries, it is assumed that the bulk of drug purchasers are not wealthy enough to afford the cost of treatment. Companies deterred from investing in anti-tuberculosis drug research postulate that if most individuals cannot afford the expense of existing treatment today, they could ill afford the cost of superior and more expensive treatment tomorrow. (...) Because of the existence of Directly Observed Treatment, Short-Course (DOTS strategy), most companies perceive no compelling reason for market entry.
Language:English
Score: 1181892.6 - https://www.who.int/tdr/public...centives-anti-tuberculosis.pdf
Data Source: un
The Code is issued by the China Enterprise Confederation (CEC) in cooperation with the International Labour Office (ILO) to help CEC member companies to take measures to promote equal opportunity and treatment and eliminate discrimination in their company policies and practices. (...) (b) Employers are encouraged to adopt specific policies and measures to promote equality of opportunity and treatment at work. 10. COMMUNICATING, RAISING AWARENESS AND BUILDING CAPACITY (a) Copies of the Code should be publicly displayed on company premises, and information about it should be disseminated amongst all employees and workers’ representatives in language they understand. (...) Read this “Code of Practice” and the related “Employers’ Guide” to get more information on how to ensure equal opportunity and treatment and elimination of any discriminatory practices in your company. 11-30 yes’s Y o u r c o m p a n y i s s t a r t i n g t o m a k e progress in implementing equality, but you still have some way to go.
Language:English
Score: 1176849.7 - https://www.ilo.org/wcmsp5/gro...ts/publication/wcms_191603.pdf
Data Source: un
Ipsen has a leading-edge technological platform in toxins that offers potential in the treatment of neuromuscular disorders, as well as for pain and aesthetic medicine. Johnson & Johnson is the world’s largest and most broadly based healthcare company. Its pharmaceutical companies are actively developing treatments for patients in six important therapeutic areas: cardiovascular and metabolism, immunology, neuroscience, infection disease and vaccines, oncology, and pulmonary hypertension. (...) The company is also pursuing development of new treatments in inflammatory pain, neuropathic pain, Alzheimer’s disease, and ADHD.
Language:English
Score: 1172528.9 - https://www.wipo.int/pat-informed/en/participants/
Data Source: un
Treatment of COVID-19 patients at the country level remains the first line of defense. (...) In all cases and regardless of treatment location, your company, either through insurance or other available means, will be responsible for any and all costs after the patient’s discharge from intensive/high dependency care, including, but not limited to, other in- patient treatment, outpatient services, room and board during the convalescent period, any applicable entitlements from your company, as well as onward or return travel to the MEDEVAC point of origin or elsewhere. (...) As part of the COVID-19 MEDEVAC System, the UN system will aim to facilitate the right of entry of the patient and any non-medical escort into the relevant country of treatment. 12. Your company will be responsible for all aspects (including costs) of any repatriation processes (including repatriation of remains), for the abovementioned eligible persons, as well as for any non-medical escorts. 13.
Language:English
Score: 1168782.1 - https://www.un.org/sites/un2.u...or_covid-19_medevac_system.pdf
Data Source: un
Treatment, reuse and recycling of hazardous waste and transforming it into useful thing 8. “Kornezit”, A Hungarian Company, winner of government organized international and national bidding, has carried out a technical and economic feasibility study on Establishing centralized treatment plant for hazardous waste 9. (...) Water and waste water issue is dealt by different ministries, and it is not clear distribution of responsibilities related to waste water treatment and reducing waste disposal in water and soil, the measures to be taken for improving waster water and toilet condition, improving sanitation infrastructure of tourist companies and decreasing environmental problem etc are left without solution. 23.
Language:English
Score: 1168560.1 - https://www.un.org/esa/dsd/dsd...onalReports/mongolia/waste.pdf
Data Source: un